The Financial Times examines the rise of product development partnerships (PDPs), which are “non-governmental organizations that generate their own funding and build partnerships with universities, businesses, government and patients in low-income countries to develop new drugs, vaccines, prevention techniques and diagnostics for diseases such as tuberculosis, HIV, malaria, cholera and meningitis.”
Private Sector Involvement
“In the first agreement between a pharmaceutical company and the new international Medicines Patent Pool, Gilead Sciences announced Tuesday that it would license four of its AIDS and hepatitis B drugs to the pool,” the New York Times reports (McNeil, 7/12).
Health ministers from Brazil, Russia, India, China, and South Africa in Beijing “on Monday vowed to improve access to low-cost and high-quality medicine â€“ and called on developed nations to shoulder responsibility in helping the poor,” Agence France-Presse reports (7/11).
EU Countries Should Pool Funding To Create ‘Prize’ For Bringing New Antibiotics To Market, Report Says
“European policy makers were urged Wednesday to find viable financial incentives to get drug companies to discover new antibiotics, because the lack of fresh supplies poses acute dangers to health care and efforts against infectious diseases,” according to a report by the Office of Health Economics and funded by GlaxoSmithKline, Dow Jones/Wall Street Journal reports.
The NIH in a press release said it will begin work on a “new programÂ to discover, develop and distribute measures of nutritional status.” The Biomarkers of Nutrition for Development (BOND) Program “brings together experts in the field of nutrition to provide advice to researchers, clinicians, program- and policymakers, on the…
Researchers from Scynexis Inc. of Research Triangle Park, N.C., and Anacor Pharmaceuticals in Palo Alto, Calif., sponsored by the Drugs for Neglected Diseases initiative, on Tuesday reported in the journal PLoS Neglected Tropical Diseases that a new experimental drug kills the parasite that causes African sleeping sickness in mice and will enter human clinical trials this year, ScienceNOW reports (Leslie, 6/28).
A post on “PharmaTech Talk” highlights comments made by USAID Administrator Rajiv Shah at the Partnerships for Global Health Forum, an annual event which is sponsored by BIO and BioVentures for Global Health. “Shah talked about the role of public-private partnerships to improve innovations in science and technology. … Shah admitted that in the past it has been hard for the private sector to engage USAID, but he made a point to say that if the biotech/pharma industry builds a breakthrough product that can save lives, USAID will help to deliver it to the populations that need it most. He said USAID is already working to better engage the private sector as well as academic institutions to make such partnerships easier to navigate, and less bureaucratic” (Drakulich, 6/27).
Writing in the Center for Global Development’s “Views From The Center” blog about the creation of a hedging tool by the World Bank and J.P. Morgan to help protect farmers from volatile food prices in developing countries,Â CGD Vice President for Corporate Affairs Todd Moss says that having safeguards in…
The social entrepreneurial organization Ashoka and pharmaceutical company Boehringer Ingelheim on Tuesday announced they are launching a three-year global initiative aimed at “promot[ing] healthy individuals, families and communities by identifying and supporting the most promising solutions to challenging health problems,” according to an Ashoka press release. The “Making More Health”…
More than 50 companies involved in global development work have formed the Coalition of International Development Companies “in hopes of gaining more visibility for their work with the U.S. Agency for International Development as well as with other government agencies and nongovernmental organizations,” Washington Technology reports.